Recent advancements in the CLL treatment landscape have prompted members of the CARE™ Faculty to discuss how these developments could affect the practice of KOLs across the globe. CARE™ Faculty spoke with Dr. Matthew Davids to explore how recent data releases and emerging clinical considerations can impact CLL practice.
This is part of the CARE™ Global Interview series and features content on:
1. Front-line CLL
BTK and BCL-2 Inhibitor Combination
2. Relapsed/Refractory CLL
PI3K and BCL-2 Inhibitor Combination
3. Clinical Considerations
Finite versus Continuous Treatment
BCL-2 Inhibitor Resistance
While CARE™ Content is typically framed from a Canadian Perspective, this series provides insights from global leaders. Content is presented in the format in which it was discussed and is a paraphrase of interview dialogue.